

LONG ISLAND BIOSCIENCE HUB SELECTS THIRD BIOENTREPRENEUR-IN-RESIDENCE

Entrepreneur Derek Brand selected to facilitate new bioscience ventures

STONY BROOK, N.Y. – December 16, 2015 – The [Center for Biotechnology at Stony Brook University](#) announced today the appointment of Derek Brand as BioEntrepreneur-In-Residence (B-EIR) for the Long Island Bioscience Hub. The Long Island Bioscience Hub is a National Institutes of Health-designated Research Evaluation and Commercialization Hub, and represents a partnership between Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, to commercialize technology emerging from their institutions.

Mr. Brand most recently served as Vice President of Business Development at Enumeral Biomedical Corp., which licensed a single cell immunology platform out of MIT and is now a publicly traded biotechnology company with a pipeline of novel immunotherapies in oncology. In addition to Enumeral, Mr. Brand has held both business and scientific roles at multiple early-stage, venture-backed biomedical startup companies; he has also held commercial leadership roles at GE and the New York Academy of Sciences and presently serves on the advisory board of AlloVate LLC, a novel allergy immunotherapy company in NYC. He received his MBA from Babson College and his B.A. in biology from Hamilton College.

“I’m excited to take on the role of BioEntrepreneur-in-Residence and looking forward to bringing a diverse array of startup experience to the LIBH community” Mr. Brand stated. “The opportunity to dig in at the earliest stages of innovation with the exceptional scientists at Long Island institutions is a terrific opportunity, and it’s an honor to have been selected.”

“Mr. Brand is an excellent addition to the team of entrepreneurs engaged in the B-EIR initiative” Diane Fabel, Director of Operations for the Center for Biotechnology stated. “We are excited to see the positive impact these entrepreneurs will have as new companies are launched within the Hub.”

Mr. Brand joins an impressive roster of seven B-EIRs that was expanded in November to include Drs. Brian McCarthy and Gian Luca Araldi. Dr. McCarthy has an extensive background as an investment analyst and as the President and CEO of the startup Influmedix while Dr. Araldi has had a distinguished career in drug discovery within the pharmaceutical industry and as the Founder and Principal of US Pharma Services.

LIBH B-EIRs are tasked with identifying technology or technologies from within the partner institutions that will create the foundation for licensing and company formation. B-EIRs will have the support of the LIBH business and technology development staff, along with external industry advisors to develop successful commercialization strategies, and position the company for SBIR/STTR grant opportunities, and Angel and VC investment. The LIBH can also provide opportunities to access development funding to help advance technologies towards

commercialization. Ultimately, the goal is to foster the creation and growth of new ventures that leverage the exceptional scientific and technological advances taking place at LIBH institutions.

Contact:

Diane Fabel

Director of Operations

diane.fabel@stonybrook.edu

631-632-8521

###

About the Long Island Bioscience Hub

The Long Island Bioscience Hub (LIBH) is a National Institutes of Health (NIH)-designated Research Evaluation and Commercialization Hub (REACH), one of just three such Hubs in the country. The REACH initiative will foster the development of therapeutics, preventatives, diagnostics, devices, and tools that address diseases within the NIH's mission. The LIBH is a partnership between the Center for Biotechnology, Stony Brook University, Cold Spring Harbor Laboratory and Brookhaven National Laboratory to commercialize biomedical innovations emerging from the partner institutions. In addition to the support provided by NIH and the partner institutions, the Long Island Bioscience Hub is supported by Empire State Development and The Research Foundation for SUNY, and represents an \$8.1M investment in technology commercialization, new company formation and entrepreneurship education. Long Island Bioscience Hub will take advantage of partnerships with the National Institutes of Health, U.S. Food and Drug Administration, the United States Patent Office, and the Centers for Medicare & Medicaid Services to support technology commercialization and company formation efforts.

About the Center for Biotechnology at Stony Brook University

Established in 1983, the Center for Biotechnology (CFB) at Stony Brook University is an Empire State Development Division of Science, Technology and Innovation (NYSTAR) Center for Advanced Technology. The Center for Biotechnology serves as an important catalyst in the development of new biomedical technologies and emerging companies in New York State. Through groundbreaking initiatives, the Center supports technology commercialization and company formation by bridging the gap between discovery and commercial success, and by training the next generation of biomedical leaders. The Center for Biotechnology also supports New York's biotechnology industry by providing access to scientific and business expertise and creating strategic infrastructure that promotes the growth of the life sciences industry in the State. The Center for Biotechnology has contributed to the development of more than a dozen FDA approved products including ReoPro®, Xiaflex®, Oracea®, Cavistat®, V3D®-Colon Virtual Colonoscopy and Exogen® Bone Healing System, among others. It has also helped launch eighteen companies.